Pharmaceutical

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Live video webcast on Wednesday, October 2nd at 12:00 PM ET LA JOLLA, CA, Sept. 25, 2024 (GLOBE NEWSWIRE) --…

4 months ago

GEN Announces Positive Phase 2 Clinical Trial Results for GN-037 Topical Cream in Patients With Mild to Moderate Plaque Psoriasis

ANKARA, TURKEY / ACCESSWIRE / September 25, 2024 / GEN Pharmaceuticals (GENIL.IS), a leading Turkish pharmaceutical company, has announced the…

4 months ago

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

SAN FRANCISCO, CA / ACCESSWIRE / September 25, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the…

4 months ago

Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders

JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development…

4 months ago

NLS Pharmaceutics Ltd. Announces Expected Implementation of 1-for-40 Reverse Share Split

ZURICH, SWITZERLAND / ACCESSWIRE / September 25, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(Nasdaq:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage…

4 months ago

Sonnet BioTherapeutics Announces 1-for-8 Reverse Stock Split

PRINCETON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (“Sonnet” or the “Company”) (NASDAQ: SONN), a biopharmaceutical…

4 months ago

Windtree Announces Positive Topline Results from Its Phase 2b SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock

Istaroxime significantly improved primary endpoint of the systolic blood pressure profile over six hours and showed significant improvements in many…

4 months ago

Mineralys Therapeutics Completes Target Enrollment in Pivotal Advance-HTN Trial of Lorundrostat for the Treatment of Hypertension

– On track to announce topline data in Q1 2025 – – Virtual KOL event scheduled on October 30th to…

4 months ago

Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology

ORION CORPORATION PRESS RELEASE 25 SEPTEMBER 2024 at 15.00 EEST                   Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation…

4 months ago

Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

– Completion of nonclinical safety and toxicity studies, Phase 1 clinical trial design and established Maximum Recommended Starting Dose –…

4 months ago